Skip to main content

Table 2 Association between clinicopathological characteristics of breast cancer patients and CDKN2B-AS1 genotypes

From: Association of cyclin-dependent kinase inhibitor 2B antisense RNA 1 gene expression and rs2383207 variant with breast cancer risk and survival

Characteristics Total A/A A/G G/G P-value
Demographics and risk factors
 Age (years)
  ≤ 45 98 (48.3) 8 (44.4) 24 (58.5) 26 (51) 0.38
  > 45 105 (51.7) 10 (55.6) 17 (41.5) 25 (49)  
 Smoking
  Negative 99 (90) 18 (100) 37 (90.2) 44 (86.3) 0.248
  Positive 11 (10) 0 (0) 4 (9.8) 7 (13.7)  
 Weight
 Underweight 12 (10.9) 4 (22.2) 4 (9.8) 4 (7.8) 0.004
  Normal 28 (25.5) 7 (38.9) 13 (31.7) 8 (15.7)  
  OW/Obese 70 (63.6) 7 (38.9) 24 (58.5) 39 (76.5)  
 FH cancer
  Negative 76 (69.1) 13 (72.2) 28 (68.3) 35 (68.6) 0.951
  Positive 34 (30.9) 5 (27.8) 13 (31.7) 16 (31.4)  
 Breast problems
  Negative 102 (92.7) 18 (100) 38 (92.7) 46 (90.2) 0.387
  Positive 8 (7.3) 0 (0) 3 (7.3) 5 (9.8)  
 OCP intake
  Negative 87 (79.1) 17 (94.4) 29 (70.7) 41 (80.4) 0.114
  Positive 23 (20.9) 1 (5.6) 12 (29.3) 10 (19.6)  
 Menarche
  Late onset 39 (35.5) 4 (22.2) 11 (26.8) 24 (47.1) 0.058
  Early onset 71 (64.5) 14 (77.8) 30 (73.2) 27 (52.9)  
 Parity
  Multipara 96 (87.3) 14 (77.8) 37 (90.2) 45 (88.2) 0.401
  Nullipara 14 (12.7) 4 (22.2) 4 (9.8) 6 (11.8)  
 Gravida
  Early G1 105 (95.5) 18 (100) 38 (92.7) 49 (96.1) 0.443
  Late G1 5 (4.5) 0 (0) 3 (7.3) 2 (3.9)  
 Menopause
  Early 98 (89.1) 16 (88.9) 37 (90.2) 45 (88.2) 0.953
  Late 12 (10.9) 2 (11.1) 4 (9.8) 6 (11.8)  
 Breast feeding
  Negative 92 (83.6) 13 (72.2) 34 (82.9) 45 (88.2) 0.284
  Positive 18 (16.4) 5 (27.8) 7 (17.1) 6 (11.8)  
 Menopausal status
  Pre 80 (72.7) 14 (77.8) 28 (68.3) 38 (74.5) 0.698
  Post 30 (27.3) 4 (22.2) 13 (31.7) 13 (25.5)  
 Night work
  Negative 97 (88.2) 16 (88.9) 36 (87.8) 45 (88.2) 0.993
  Positive 13 (11.8) 2 (11.1) 5 (12.2) 6 (11.8)  
 Sedentary life style
  Negative 11 (10) 1 (5.6) 3 (7.3) 7 (13.7) 0.470
  Positive 99 (90) 17 (94.4) 38 (92.7) 44 (86.3)  
Pathological data
 Side
  Right 70 (63.6) 11 (61.1) 27 (65.9) 32 (62.7) 0.92
  Left 40 (36.4) 7 (38.9) 14 (34.1) 19 (37.3)  
 Site
  Outer quadrants 48 (43.6) 5 (27.8) 16 (39) 27 (52.9) 0.13
  Others 62 (56.4) 13 (72.2) 25 (61) 24 (47.1)  
 No masses
  Single 85 (77.3) 12 (66.7) 30 (73.2) 43 (84.3) 0.22
  Multiple 25 (22.7) 6 (33.3) 11 (26.8) 8 (15.7)  
 Grade
  ≤ 2 90 (81.8) 16 (88.9) 32 (78) 42 (82.4) 0.60
  > 2 20 (18.2) 2 (11.1) 9 (22) 9 (17.6)  
 T stage
  ≤ 3 79 (71.8) 12 (66.7) 29 (70.7) 38 (74.5) 0.80
  > 3 31 (28.2) 6 (33.3) 12 (29.3) 13 (25.5)  
 N stage
  N0 30 (27.3) 8 (44.4) 10 (24.4) 12 (23.5) 0.20
  N1–3 80 (72.7) 10 (55.6) 31 (75.6) 39 (76.5)  
 M stage
  M0 50 (45.5) 8 (44.4) 17 (41.5) 25 (49) 0.76
  M1 60 (54.5) 10 (55.6) 24 (58.5) 26 (51)  
 LVI
  Negative 58 (52.7) 10 (55.6) 18 (43.9) 30 (58.8) 0.35
  Positive 52 (47.3) 8 (44.4) 23 (56.1) 21 (41.2)  
 Skin involvement
  Negative 89 (80.9) 14 (77.8) 31 (75.6) 44 (86.3) 0.40
  Positive 21 (19.1) 4 (22.2) 10 (24.4) 7 (13.7)  
 Clinical stage
  ≤ 2 48 (43.6) 8 (44.4) 17 (41.5) 23 (45.1) 0.93
  > 2 62 (56.4) 10 (55.6) 24 (58.5) 28 (54.9)  
 NPI
  Good 56 (50.9) 12 (66.7) 19 (46.3) 25 (49) 0.332
  Poor 54 (49.1) 6 (33.3) 22 (53.7) 26 (51)  
 Molecular subtype
  Luminal A 52 (47.3) 9 (50) 16 (39) 27 (52.9) 0.45
  Luminal B 14 (12.7) 3 (16.7) 3 (7.3) 8 (15.7)  
  HER2+ 7 (6.4) 1 (5.6) 4 (9.8) 2 (3.9)  
  Basal 37 (33.6) 5 (27.8) 18 (43.9) 14 (27.5)  
 IHPI
  Good 66 (181.6) 12 (66.7) 19 (46.3) 35 (68.6) 0.25
  Moderate 37 (33.6) 5 (27.8) 18 (43.9) 14 (27.5)  
  Poor 7 (6.4) 1 (5.6) 4 (9.8) 2 (3.9)  
Follow-up
 ESMO
  Low risk 41 (37.3) 9 (50) 16 (39) 16 (31.4) 0.35
  High risk 69 (62.7) 9 (50) 25 (61) 35 (68.6)  
 DFS
  Prolonged 52 (47.3) 7 (38.9) 13 (31.7) 32 (62.7) 0.009
  Short 58 (52.7) 11 (61.1) 28 (68.3) 19 (37.3)  
 Recurrence
  Negative 55 (50) 9 (50) 19 (46.3) 27 (52.9) 0.82
  Positive 55 (50) 9 (50) 22 (53.7) 24 (47.1)  
 OS
  Prolonged 53 (48.2) 2 (11.1) 8 (19.5) 43 (84.3) < 0.001
  Short 57 (51.8) 16 (88.9) 33 (80.5) 8 (15.7)  
  1. Data are presented as numbers (percentage). A two-sided Chi-square test was used. Short survival was set at 12 months. Bold values indicate significance at P-value < 0.05
  2. OW over-weight, FH family history, OCP oral contraceptive pills, G1 first pregnancy, LVI lymphovascular invasion, NPI Nottingham prognostic index, IHPI immunohistochemistry prognostic index, ESMO European Society of Medical Oncology for risk estimation of recurrence, DFS disease-free survival, OS overall survival